EQUITY (Details Narrative) - USD ($)						12 Months Ended
	Apr. 19, 2021	Feb. 08, 2021	Feb. 03, 2021	Mar. 14, 2017	Jul. 07, 2016	Dec. 31, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Reverse stock split	one-for-fifteen reverse stock split of its common stock
Common stock, par value	$ 0.0001					$ 0.0001	$ 0.0001
Warrants to purchase common stock						1,793,815
Capital stock shares authorized						155,000,000
Capital stock par value						$ 0.0001
Common stock shares authorized						150,000,000	150,000,000
Stock option grants in period						154,508
Stock option description						154,508 options granted during the year ended December 31, 2022, 109,839 options are subject to a three-year vesting period, with one-third of such awards vesting each year and 44,669 options with performance conditions, mainly related to clinical activities.
Three Year Vesting Period [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option grants in period						109,839
Performance Conditions [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option grants in period						44,669
Share-Based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Stock option grants in period						154,508	225,225
Fair value of stock options						$ 360,356	$ 1,026,000
Vesting period						3 years
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise prices ranging						$ 2.61	$ 3.89
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise prices ranging						$ 2.97	$ 10.05
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock granted						45,494	419,943
Fair value of restricted shares						$ 109,886	$ 1,781,981
Stock vesting period						3 years
Weighted average of the remaining contractual life of vested and exercisable options						8 years 4 months 28 days
Aggregate intrinsic value of exercisable options						$ 0
Weighted average fair value of options granted						2.56
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Stock granted							146,567
Stock vesting period							3 years
Fair value of restricted stock units							$ 603,856
Employee and Non-employee Stock Options [Member]
Subsidiary, Sale of Stock [Line Items]
Unvested stock-based compensation						$ 1,300,000
Unvested stock-based compensation weighted-average period for recognition						10 months 6 days
Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock convertible, shares							17,303
Converted preferred stock							207,528
Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock outstanding						1,718	1,718
Preferred stock shares authorized						1,172,000	1,172,000
Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering			89,445
Shares Issued, Price Per Share			$ 10.062
Proceeds from sale of stock			$ 900,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering							3,133,775
Preferred Stock Blank Check [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock shares authorized						5,000,000
Underwritten Public Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, par value		$ 0.0001
Number of issuance of public offering		1,935,484
Shares Issued, Price Per Share		$ 9.30
Net proceeds from issuance of stock		$ 18,900,000
Underwritten Public Offering [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering							1,225,412
Over allotment shares		290,322
Proceeds from sale of stock							$ 9,469,000
Underwritten Public Offering [Member] | Series G Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Over allotment shares		145,161
Shares Issued, Price Per Share		$ 10.23
Warrants and rights outstanding, term		5 years
Warrants exercise price							$ 10.23
Underwritten Public Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants and rights outstanding, term		5 years
Warrants to purchase common stock		111,290
Warrants exercise price		$ 10.23
Underwritten Public Offering [Member] | Series F Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price							$ 7.425
At The Market Offering [Member] | Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering					442,424
At The Market Offering [Member] | Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering				1,069,822
Converted preferred stock						2,284	2,284
Preferred stock outstanding						1,718	1,718
At The Market Offering [Member] | Series C Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock convertible, shares							625
At The Market Offering [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering							818,523
Net proceeds from issuance of stock							$ 5,453,000
Converted preferred stock							831
At The Market Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding						1,793,815